A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT- 330 in Patients With Advanced or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT- 330 in Patients With Advanced or Metastatic Solid Tumor Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Adenocarcinoma; Anaplastic astrocytoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Karyopharm Therapeutics; NPM Pharma
  • Most Recent Events

    • 31 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2016 According to Karyopharm media release, data from this trial were published in Clinical Cancer Research Publication.
    • 23 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top